Table 1.

Characteristics of subjects (n = 154) and glaucoma drug trials (n = 168)

	Mean	(Standard deviation)	Number.	Per cent.
Male sex			68	44%
Black race (n = 142)			111	78%
Trial of:
Latanoprost			86	51%
Timolol only			33	20%
Dorzolamide only			24	14%
Timolol/dorzolamide combination			1	1%
Brimonidine			17	10%
Bimatoprost			6	4%
Pilocarpine			1	1%
Age (years)	62.7	(11.8)
Baseline IOP, eye 1* (mmHg)	20.2	(5.3)
Baseline IOP, eye 2* (mmHg)	18.3	(5.2)
Uniocular trial IOP, eye 1 (mmHg)	15.3	(4.0)
Uniocular trial IOP, eye 2 (mmHg)	17.4	(5.6)
Followup IOP, mean, eye 1 (mmHg)	16.1	(3.4)
Followup IOP, mean, eye 2 (mmHg)	16.3	(4.5)

* Eye 1 is the initially treated eye. Eye 2 is the other eye.